We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-20.62%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.84B
AUM Growth
-$1.19B
Cap. Flow
+$214M
Cap. Flow %
5.56%
Top 10 Hldgs %
54.93%
Holding
140
New
25
Increased
22
Reduced
18
Closed
27

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$104M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$59.7M
3
ZYME icon
Zymeworks
ZYME
+$47.4M
4
NVRO
NEVRO CORP.
NVRO
+$39.5M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$33.6M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$152M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$78.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$53.8M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$37.3M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$23.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Financials 0.28%
3 Technology 0.27%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
76
Zimmer Biomet
ZBH
$18.8B
$4.91M 0.13%
51,500
– –
LITS
77
Lite Strategy Inc
LITS
$32.4M
$4.88M 0.13%
+151,522
New +$6.06M
ISEE
78
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.74M 0.12%
1,377,289
+387,000
+39% +$2.26M
IDYA icon
79
IDEAYA Biosciences
IDYA
$3.43B
$4.7M 0.12%
1,141,484
– –
ONEM
80
DELISTED
1Life Healthcare
ONEM
$3.31M 0.09%
+185,000
New +$4.06M
DMTK
81
DELISTED
DermTech, Inc. Common Stock
DMTK
$3.21M 0.08%
+285,856
New +$3.51M
GRTX
82
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$3.09M 0.08%
325,000
– –
ABEO icon
83
Abeona Therapeutics
ABEO
$355M
$3.06M 0.08%
60,000
– –
LSACU
84
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$2.94M 0.08%
+300,000
New +$2.97M
MOTS
85
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$2.84M 0.07%
14,035
– –
RYTM icon
86
Rhythm Pharmaceuticals
RYTM
$7.31B
$2.6M 0.07%
170,859
– –
ATEC icon
87
Alphatec Holdings
ATEC
$1.48B
$2.02M 0.05%
561,574
– –
PHR icon
88
Phreesia
PHR
$689M
$1.42M 0.04%
70,000
– –
BIO icon
89
Bio-Rad Laboratories Class A
BIO
$8.76B
$1.22M 0.03%
3,489
-65,000
-95% -$23.9M
AXNX
90
DELISTED
Axonics, Inc. Common Stock
AXNX
$1.19M 0.03%
50,000
-5,000
-9% -$149K
TXMD icon
91
TherapeuticsMD
TXMD
$23.8M
$1.17M 0.03%
21,922
– –
RACE icon
92
Ferrari
RACE
$67.8B
$957K 0.02%
6,200
– –
EIGR
93
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$951K 0.02%
4,663
– –
MNTA
94
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$881K 0.02%
30,637
-2,805,000
-99% -$78.1M
ZGNX
95
PUT
DELISTED
Zogenix, Inc.
ZGNX
$724K 0.02%
+300,000
New +$10.9M
SRRA
96
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$664K 0.02%
66,654
-1
-0% -$13
XLRN
97
DELISTED
Acceleron Pharma
XLRN
$583K 0.02%
+6,813
New +$530K
KRMD icon
98
KORU Medical Systems
KRMD
$187M
$537K 0.01%
74,813
– –
KRTX
99
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$497K 0.01%
6,944
– –
CCXI
100
DELISTED
ChemoCentryx, Inc.
CCXI
$406K 0.01%
+10,252
New +$435K
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Perceptive Advisors held 140 positions worth $3.84B, down 24% from $5.03B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors deployed $214M of net new capital in Q1 2020, opening 25 new positions and adding to 22 existing holdings. Its largest new stake was Gilead Sciences: 1,500,000 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Momenta Pharmaceuticals, Inc., an estimated $78.1M trimmed.

  • Perceptive Advisors's largest Q1 2020 buy was Gilead Sciences: 1,500,000 shares worth $11.2M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2020, an estimated $59.7M increase.
  • Perceptive Advisors's biggest Q1 2020 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $78.1M.
  • Perceptive Advisors fully exited Amarin Corp in Q1 2020, selling an estimated $152M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $3.84B portfolio in Q1 2020.
  • Perceptive Advisors opened 25 new positions and closed 27 in Q1 2020.
  • Perceptive Advisors's portfolio value fell 24% quarter-over-quarter to $3.84B.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.